$6.46
6.24% today
Nasdaq, Apr 04, 07:16 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Intellia Therapeutics, Inc. Classifications & Recommendation:

Buy
71%
Hold
25%
Sell
4%

Intellia Therapeutics, Inc. Price Target

Target Price $41.78
Price $6.89
Potential
Number of Estimates 23
23 Analysts have issued a price target Intellia Therapeutics, Inc. 2026 . The average Intellia Therapeutics, Inc. target price is $41.78. This is higher than the current stock price. The highest price target is
$106.00 1,438.46%
register free of charge
, the lowest is .
A rating was issued by 28 analysts: 20 Analysts recommend Intellia Therapeutics, Inc. to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Intellia Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 57.88 49.44
59.54% 14.58%
EBITDA Margin -905.29% -1,007.71%
35.13% 11.31%
Net Margin -925.46% -963.86%
39.28% 4.15%

24 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2025 . The average Intellia Therapeutics, Inc. sales estimate is

$49.4m
Unlock
. This is
14.58% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$210m 262.82%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $57.9m 59.54%
2025
$49.4m 14.58%
Unlock
2026
$42.9m 13.24%
Unlock
2027
$364m 748.70%
Unlock
2028
$1.2b 219.20%
Unlock
2029
$2.8b 138.43%
Unlock

6 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2025. The average Intellia Therapeutics, Inc. EBITDA estimate is

$-498m
Unlock
. This is
4.92% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-372m 29.02%
Unlock
, the lowest is
$-599m 14.37%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-524m 3.49%
2025
$-498m 4.92%
Unlock
2026
$-520m 4.44%
Unlock
2027
$-591m 13.60%
Unlock

EBITDA Margin

2024 -905.29% 35.13%
2025
-1,007.71% 11.31%
Unlock
2026
-1,213.07% 20.38%
Unlock
2027
-162.37% 86.61%
Unlock

25 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Intellia Therapeutics, Inc. net profit estimate is

$-477m
Unlock
. This is
11.04% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-325m 39.24%
Unlock
, the lowest is
$-583m 8.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-536m 3.14%
2025
$-477m 11.04%
Unlock
2026
$-449m 5.69%
Unlock
2027
$-223m 50.31%
Unlock
2028
$217m 196.99%
Unlock
2029
$1.2b 450.24%
Unlock

Net Margin

2024 -925.46% 39.28%
2025
-963.86% 4.15%
Unlock
2026
-1,047.76% 8.70%
Unlock
2027
-61.35% 94.14%
Unlock
2028
18.64% 130.38%
Unlock
2029
43.02% 130.79%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.25 -4.67
3.14% 11.05%
P/E negative
EV/Sales 6.51

25 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. EPS is

$-4.67
Unlock
. This is
11.05% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.19 39.24%
Unlock
, the lowest is
$-5.71 8.76%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.25 3.14%
2025
$-4.67 11.05%
Unlock
2026
$-4.40 5.78%
Unlock
2027
$-2.19 50.23%
Unlock
2028
$2.12 196.80%
Unlock
2029
$11.68 450.94%
Unlock

P/E ratio

Current -1.31 74.21%
2025
-1.48 12.98%
Unlock
2026
-1.56 5.41%
Unlock
2027
-3.15 101.92%
Unlock
2028
3.25 203.17%
Unlock
2029
0.59 81.85%
Unlock

Based on analysts' sales estimates for 2025, the Intellia Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of
14.43
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.56 89.08%
2025
6.51 17.10%
Unlock
2026
7.51 15.27%
Unlock
2027
0.88 88.22%
Unlock
2028
0.28 68.68%
Unlock
2029
0.12 58.05%
Unlock

P/S ratio

Current 12.32 83.09%
2025
14.43 17.07%
Unlock
2026
16.63 15.27%
Unlock
2027
1.96 88.22%
Unlock
2028
0.61 68.67%
Unlock
2029
0.26 58.06%
Unlock

Current Intellia Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 05 2025
Truist Securities
Locked
Locked
Locked Mar 04 2025
Wells Fargo
Locked
Locked
Locked Feb 28 2025
Barclays
Locked
Locked
Locked Feb 28 2025
Citigroup
Locked
Locked
Locked Feb 28 2025
JP Morgan
Locked
Locked
Locked Feb 28 2025
Chardan Capital
Locked
Locked
Locked Feb 28 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 05 2025
Locked
Truist Securities:
Locked
Locked
Mar 04 2025
Locked
Wells Fargo:
Locked
Locked
Feb 28 2025
Locked
Barclays:
Locked
Locked
Feb 28 2025
Locked
Citigroup:
Locked
Locked
Feb 28 2025
Locked
JP Morgan:
Locked
Locked
Feb 28 2025
Locked
Chardan Capital:
Locked
Locked
Feb 28 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today